MA45517A - Molécules de liaison inhibant la croissance de cancer - Google Patents

Molécules de liaison inhibant la croissance de cancer

Info

Publication number
MA45517A
MA45517A MA045517A MA45517A MA45517A MA 45517 A MA45517 A MA 45517A MA 045517 A MA045517 A MA 045517A MA 45517 A MA45517 A MA 45517A MA 45517 A MA45517 A MA 45517A
Authority
MA
Morocco
Prior art keywords
binding molecules
cancer growth
inhibit cancer
membrane
molecules inhibit
Prior art date
Application number
MA045517A
Other languages
English (en)
Other versions
MA45517B1 (fr
Inventor
Eduard Batlle
Johannes Carolus Clevers
Bram Herpers
Ton Logtenberg
Mark Throsby
Robert Gerhardus Jacob Vries
Original Assignee
Fundacio Inst De Recerca Biomedica Irb Barcelona
Inst Catalana Recerca Estudis Avancats
Koninklijke Nederlandse Akademie Van Wetenschappen
Merus Nv
Ocello B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca Biomedica Irb Barcelona, Inst Catalana Recerca Estudis Avancats, Koninklijke Nederlandse Akademie Van Wetenschappen, Merus Nv, Ocello B V filed Critical Fundacio Inst De Recerca Biomedica Irb Barcelona
Publication of MA45517A publication Critical patent/MA45517A/fr
Publication of MA45517B1 publication Critical patent/MA45517B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des moyens et des procédés pour inhiber la croissance d'un cancer. Les moyens, dans certains modes de réalisation, comprennent des protéines et des anticorps qui se lient à une partie extracellulaire d'un membre de la famille du récepteur du facteur de croissance épidermique (egf) associé à la membrane et à une partie extracellulaire d'un élément d'une voie de signalisation wnt associé à la membrane. L'invention concerne en outre diverses cellules et tests qui sont utiles pour produire des protéines, des anticorps et des cellules.
MA45517A 2015-10-23 2016-10-21 Molécules de liaison inhibant la croissance de cancer MA45517B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15191343 2015-10-23
EP16168647 2016-05-06
PCT/NL2016/050726 WO2017069628A2 (fr) 2015-10-23 2016-10-21 Molécules de liaison inhibant la croissance de cancer

Publications (2)

Publication Number Publication Date
MA45517A true MA45517A (fr) 2018-08-29
MA45517B1 MA45517B1 (fr) 2021-04-30

Family

ID=57190021

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054760A MA54760A (fr) 2015-10-23 2016-10-21 Molécules de liaison qui inhibent la croissance d'un cancer
MA45517A MA45517B1 (fr) 2015-10-23 2016-10-21 Molécules de liaison inhibant la croissance de cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA054760A MA54760A (fr) 2015-10-23 2016-10-21 Molécules de liaison qui inhibent la croissance d'un cancer

Country Status (25)

Country Link
US (2) US11939394B2 (fr)
EP (2) EP3365373B1 (fr)
JP (3) JP7296728B2 (fr)
KR (2) KR20250157457A (fr)
CN (2) CN108602888B (fr)
AU (2) AU2016340764B2 (fr)
CA (1) CA3002957A1 (fr)
CY (1) CY1124108T1 (fr)
DK (1) DK3365373T3 (fr)
EA (1) EA201890866A1 (fr)
ES (1) ES2865482T3 (fr)
HR (1) HRP20210483T1 (fr)
HU (1) HUE055222T2 (fr)
LT (1) LT3365373T (fr)
MA (2) MA54760A (fr)
MD (1) MD3365373T2 (fr)
MX (2) MX389547B (fr)
NZ (1) NZ742290A (fr)
PL (1) PL3365373T3 (fr)
RS (1) RS61800B1 (fr)
SG (1) SG11201803359VA (fr)
SI (1) SI3365373T1 (fr)
SM (1) SMT202100230T1 (fr)
WO (1) WO2017069628A2 (fr)
ZA (1) ZA201802758B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3786186A1 (fr) 2014-02-28 2021-03-03 Merus N.V. Anticorps qui se lient aux egfr et erbb3
AU2015240599B2 (en) * 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
WO2017069628A2 (fr) 2015-10-23 2017-04-27 Merus N.V. Molécules de liaison inhibant la croissance de cancer
KR20180138205A (ko) 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
EP3568158A4 (fr) * 2017-01-11 2020-11-18 The Board of Trustees of the Leland Stanford Junior University Molécules de substitution de r-spondine (rspo)
WO2018140821A1 (fr) * 2017-01-26 2018-08-02 Surrozen, Inc. Molécules d'amélioration de signal wnt spécifiques au tissu et leurs utilisations
WO2018182420A1 (fr) * 2017-03-31 2018-10-04 Merus N.V. Anticorps pour le traitement de tumeurs positives erbb-2/erbb-3
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
EA202090005A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
MX2020000055A (es) * 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
SG11202009036YA (en) * 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
EP3820499A4 (fr) * 2018-07-09 2022-07-13 Surrozen Operating, Inc. Molécules d'amélioration de signaux wnt spécifiques au tissu et leurs utilisations
WO2020139950A1 (fr) * 2018-12-27 2020-07-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Anticorps bispécifique pour clairance membranaire de récepteurs cibles
CN114249823A (zh) * 2018-12-31 2022-03-29 美勒斯公司 混合的结合域
WO2020141974A1 (fr) 2018-12-31 2020-07-09 Merus N.V. Multimères multivalents tronqués
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
IL285490B2 (en) * 2019-02-14 2026-03-01 Merus Nv Combinations of binding sites that bind EGFR, HER2, and HER3
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
TWI862565B (zh) * 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US20230084382A1 (en) * 2019-08-19 2023-03-16 Merus N.V. Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor
KR20220091559A (ko) * 2019-11-01 2022-06-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 이중특이적 결합제를 사용한 표면 단백질의 분해
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
EP4114854A1 (fr) * 2020-03-05 2023-01-11 UMC Utrecht Holding B.V. Ubiquitine ligases membranaires pour cibler la dégradation de protéines
US20230184745A1 (en) * 2020-03-05 2023-06-15 Umc Utrecht Holding B.V. Screening method for effective target - E3 ligase combinations
CN115698067A (zh) 2020-04-24 2023-02-03 美勒斯公司 使用结合lgr5及egfr的抗体的癌症治疗
CN118717980A (zh) * 2020-09-08 2024-10-01 复旦大学 ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用
JP7714992B2 (ja) * 2020-10-02 2025-07-30 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
CA3198268A1 (fr) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Molecules d'amelioration de signaux wnt specifiques du fois et leurs utilisations
MX2023006983A (es) * 2020-12-15 2023-06-26 Merus Nv Tratamiento de canceres con un anticuerpo que se une al receptor 5 acoplado a proteina g (lgr5) y al receptor del factor de crecimiento epidermico (egfr).
CN117582496A (zh) * 2020-12-18 2024-02-23 美勒斯公司 抗体组合物
CN114853889B (zh) * 2021-02-03 2024-03-01 中国科学院动物研究所 针对人gpr48的单克隆抗体及其应用
MX2023011663A (es) * 2021-03-31 2023-10-11 Merus Nv Dominios de union a pd-1 novedosos.
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
CA3237654A1 (fr) 2021-10-06 2023-04-13 Merus N.V. Traitement de cancers traites par un inhibiteur de point de controle immunitaire ayant une expression d'egfr elevee a l'aide d'un anticorps se liant au moins a l'egfr
CN122031678A (zh) 2022-12-23 2026-05-15 美勒斯公司 使用至少结合egfr的抗体及免疫检查点抑制剂组合治疗癌症
WO2024144401A1 (fr) 2022-12-28 2024-07-04 Merus N.V. Traitement du cancer avec une combinaison d'un anticorps qui se lie à l'egfr et de médicaments cytotoxiques
CN116082510B (zh) * 2023-03-07 2023-12-05 四川尚锐生物医药有限公司 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
FI940144A7 (fi) 1991-07-15 1994-01-12 The Wellcome Foundation Ltd Vasta-aineiden tuotanto
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 E. Missel GmbH & Co., 70374 Stuttgart Trägersystem für Bade-, Dusch- oder Whirlwannen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CN100457914C (zh) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
DE29915950U1 (de) 1999-09-10 1999-12-30 CMW Automation GmbH, 65594 Runkel Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
EP1806407B1 (fr) 2001-07-04 2010-05-05 Chromagenics B.V. Séquences d'ADN avec une activité anti-repressor
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
EP1510943A4 (fr) 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc Dispositif de prediction d'interactions
EP2314629B2 (fr) 2002-07-18 2022-11-16 Merus N.V. Production recombinante de mélanges d'anticorps
CA2512647C (fr) 2003-01-07 2013-10-08 Symphogen A/S Methode de production de proteines polyclonales de recombinaison
WO2005000894A2 (fr) 2003-06-25 2005-01-06 Crucell Holland B.V. Molecules de liaison pour traiter les malignites de cellules myeloides
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
CA2577082A1 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
WO2007110205A2 (fr) 2006-03-24 2007-10-04 Merck Patent Gmbh Domaines de proteine heterodimerique d'ingenierie
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
EP2091975A4 (fr) 2006-11-21 2013-05-22 Univ California Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
HRP20151261T1 (hr) 2007-07-02 2016-01-01 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za lijeäśenje i dijagnosticiranje raka
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
EP2235536A4 (fr) 2007-12-20 2011-05-04 Lab Corp America Holdings Procédés de diagnostic du her-2
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
CA2715043C (fr) 2008-02-05 2021-02-16 Zymeworks Inc. Procedes de determination de residus correles dans une proteine ou autre biopolymere mettant en oeuvre la dynamique moleculaire
RU2731084C2 (ru) 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
EP2331577B1 (fr) 2008-08-29 2017-06-07 Symphogen A/S Compositions de l'anticorps de recombinaison anti-récepteur du facteur de croissance anti-épidermique egfr
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
EP2389392A1 (fr) 2009-01-26 2011-11-30 Genmab A/S Procédés pour produire des mélanges d'anticorps
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
KR20120059568A (ko) 2009-08-21 2012-06-08 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ３의 엑토도메인에 대한 항체 및 이의 용도
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
EP2496598B1 (fr) 2009-11-04 2017-08-02 Affibody AB Polypeptides de liaison de her3
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
EP2569337A1 (fr) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Protéines hétérodimériques et leurs procédés de production et de purification
AU2011290480B2 (en) 2010-08-16 2015-07-30 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CN103547598A (zh) 2011-02-24 2014-01-29 梅里麦克制药股份有限公司 包含抗-erbb3药剂的联合治疗
JP2014509593A (ja) 2011-03-15 2014-04-21 メリマック ファーマシューティカルズ インコーポレーティッド ＥｒｂＢ経路阻害剤に対する耐性の克服
AU2012235758B2 (en) 2011-03-25 2015-05-07 IGI Therapeutics SA Hetero-dimeric immunoglobulins
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
US9346883B2 (en) 2011-05-13 2016-05-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies against HER3
KR20140033152A (ko) 2011-06-20 2014-03-17 교와 핫꼬 기린 가부시키가이샤 항erbB3 항체
JP6185463B2 (ja) * 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ結合剤およびその使用法
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
TW201331225A (zh) 2011-12-05 2013-08-01 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之域ｉｉｉ及域ｉｖ之ｈｅｒ３抗體
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
US9702824B2 (en) 2012-03-09 2017-07-11 Promega Corporation pH sensors
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
AR090549A1 (es) * 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
CA2883264A1 (fr) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Ligands her2 bispecifiques pour la therapie du cancer
ES2831374T3 (es) * 2012-11-21 2021-06-08 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
BR112015023074A2 (pt) * 2013-03-14 2017-11-21 Oncomed Pharm Inc agentes de ligação-met e uso dos mesmos
CA2908515A1 (fr) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systemes et procedes pour faciliter le diagnostic, le pronostic et le traitement d'un cancer sur la base de la detection de l'activation de her3
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (fr) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Ciblage de her2 et her3 avec des anticorps bispécifiques dans des cellules cancéreuses
MX379030B (es) * 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
EP3786186A1 (fr) 2014-02-28 2021-03-03 Merus N.V. Anticorps qui se lient aux egfr et erbb3
SMT202500020T1 (it) 2014-02-28 2025-03-12 Merus Nv Anticorpo che lega erbb-2 ed erbb-3
MY178160A (en) * 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
AU2016293942B2 (en) 2015-07-10 2022-06-16 Merus B.V. Human CD3 binding antibody
WO2017069628A2 (fr) * 2015-10-23 2017-04-27 Merus N.V. Molécules de liaison inhibant la croissance de cancer
CN108367053A (zh) * 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
WO2018182420A1 (fr) 2017-03-31 2018-10-04 Merus N.V. Anticorps pour le traitement de tumeurs positives erbb-2/erbb-3
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
CN114008071B (zh) * 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法

Also Published As

Publication number Publication date
ZA201802758B (en) 2020-08-26
HRP20210483T1 (hr) 2021-07-09
KR20180100305A (ko) 2018-09-10
AU2023222928A1 (en) 2023-09-21
NZ742290A (en) 2019-11-29
CA3002957A1 (fr) 2017-04-27
HK1253914A1 (en) 2019-07-05
US20240343824A1 (en) 2024-10-17
CN108602888A (zh) 2018-09-28
WO2017069628A2 (fr) 2017-04-27
MX2022000302A (es) 2022-02-03
US11939394B2 (en) 2024-03-26
WO2017069628A9 (fr) 2017-10-26
WO2017069628A3 (fr) 2017-09-08
KR102877714B1 (ko) 2025-10-29
EA201890866A1 (ru) 2018-09-28
MX2018004988A (es) 2018-11-09
SMT202100230T1 (it) 2021-07-12
CY1124108T1 (el) 2022-05-27
ES2865482T3 (es) 2021-10-15
SI3365373T1 (sl) 2021-08-31
RS61800B1 (sr) 2021-06-30
KR20250157457A (ko) 2025-11-04
EP3365373B1 (fr) 2021-03-10
CN115925944A (zh) 2023-04-07
PL3365373T3 (pl) 2021-08-23
AU2016340764B2 (en) 2023-06-01
MA45517B1 (fr) 2021-04-30
CN108602888B (zh) 2022-10-04
SG11201803359VA (en) 2018-05-30
MX389547B (es) 2025-03-20
MD3365373T2 (ro) 2021-08-31
LT3365373T (lt) 2021-05-25
JP7296728B2 (ja) 2023-06-23
JP2019500405A (ja) 2019-01-10
JP2024023445A (ja) 2024-02-21
EP3365373A2 (fr) 2018-08-29
EP3912998A2 (fr) 2021-11-24
US20180312604A1 (en) 2018-11-01
JP2023008754A (ja) 2023-01-19
MA54760A (fr) 2022-04-13
DK3365373T3 (da) 2021-04-06
EP3912998A3 (fr) 2022-02-23
AU2016340764A1 (en) 2018-05-17
BR112018008068A2 (en) 2018-11-13
HUE055222T2 (hu) 2021-11-29
NZ759325A (en) 2025-05-30

Similar Documents

Publication Publication Date Title
MA45517B1 (fr) Molécules de liaison inhibant la croissance de cancer
CU24058B1 (es) Antagonistas de pcsk9
NI200900081U (es) Anticuerpos agonistas de trkb y sus usos.
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
EA201070270A1 (ru) Пептиды с пониженным уровнем образования димеров
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
EP2331136A4 (fr) Agents se liant aux récepteurs frizzled et leurs utilisations
MY155621A (en) Axl antibodies
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
MY186352A (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MX2010004374A (es) Armazones proteinicos.
MX353984B (es) Anticuerpos multi-especificos.
MA38498B1 (fr) Protéines de liaison anti-lag-3
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA201500316A1 (ru) Антагонисты толл-подобного рецептора 3
MX2010000981A (es) Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune.
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
ATE437370T1 (de) Pharmakodynamische tests mit durchflusszytometrie